1Milker-Zabel S, Debus J, Thilmann C, et al. Fractionated stereotantically guidee radiotherapy and radiosurgery in the treatment offunctional and nonfunctional adenomas of the pituitary gland, lnt J Radiat Oncol Biol Phys, 2001, 50: 1279-1286.
2Mulroy L, Rheaume DE, Fleetwood 1, et al. Stereotaetie radiation for pituitary adenoma. CMAJ,2004, 170: 320.
3Kokubo M, Sasai K, Shibamoto Y, et al. Long-term results of radiation therapy for pituitary adenoma. J Neurooncol, 2000, 47: 79-84.
4Ryohei S, Masao M, Yoshiaki O, et al. The efficacy of conventional radiation therapy in the management of pituitary adenoma. Int J Radiat Oncol Biol Phys, 2000, 47:1337-1345.
5Becker G, Kocher M, Kortmann RD, et al. Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol, 2002, 178: 173-186.
6Barrande M, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in aeromegaly: long-term results in 128 patients followed in a single center. J Clin Endocfinol Metab, 2000, 85 : 3779-3785.
7Petrovich Z, Jozsef G, Yu C, et al. Radiotherapy and stereotactic radiosurgery for pituitary tumors. Neurosurg Clin N Am, 2003, 14:147-166.
8Shin M. Gamma knife radiosurgery for pituitary adenoma. Biomed Pharmacother, 2002,56(Suppl 1) : 178-181.
9Jason P, Sheehan MD, John F, et al. Radiosurgery for nonfunctioning pituitary adenoma. Neurosurg Focus, 2003, 14(5) : 1-10.
2Schnfidt MH, Broil R, Bruch HP, et al. Proliferation marker pKi- 67 occurs in different isoforms with various cellular effects [ J ]. J Cell Biochem ,2004,91 ( 6 ) : 1280-1292.
3Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative aetivity and invasiveness among pituitary adenomas and carcinomas: an a- nalysis using the MIB-1 antibody [ J ]. Neurosurgery, 1996,38 ( 1 ) : 99-106,106-107.
4Widhalm G, Wolfsberger S, Preusser M, et al. Residual norffunc- tioning pituitary adenomas:prognostic value of MIB-I labeling index for tumor progression [ J ]. J Neurosurg,2009,111 ( 3 ) :563-571.
5Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with inva- sion of the cavernous sinus space : a magnetic resonance imaging classification compared with surgical findings [ J ]. Neurosurgery, 1993,33(4) :610-617, 617-618.
6Martins AN, Hayes GJ, Kempe LG. hwasive pituitary adenomas [ J]. J Neurosurg, 1965,22:268-276.
7Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary turnouts : merits and pitfalls of temozolomide treatment[J]. Clin Endocrinol(Oxf) ,2012,76(6) :769-775.
8Magagna-Poveda A, Leske H, Schmid C, et al. Expression of som- atostatin receptors, angiogenesis and proliferation markers in pitui- taradenomas : an immunohistochemical study with diagnostic and therapeutic implications[J]. Swiss Med Wkly,2013,143 :w13895.
9Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary ade- nomas [ J ]. J Mol Endocrinol, 2012,49 ( 2 ) : R69-R78.
10Mastronardi L, Guiducci A. Are nonfunctioning pituitary adeno- mas extending into the cavernous sinus aggressive and/or invasive [ J ] ? Neurosurgery,2002,51 (2) :521-522, 522.
